The FDA Revokes Its Emergency Use Authorization for Hydroxychloroquine
So far, no studies have shown that the anti-malarial drug can fight Covid-19, and agency officials say its potential benefits do not outweigh its risks.
So far, no studies have shown that the anti-malarial drug can fight Covid-19, and agency officials say its potential benefits do not outweigh its risks.
